Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Kamada Ltd. KMDA, +0.74% (tase:KMDA),a plasma-derived protein therapeutics company focused on orphan indications, announces that a comprehensive review of the data available in the literature in support of the mechanism of action of Alpha-1 Antitrypsin (AAT) for the treatment of Type-1 Diabetes, was published in the August 2014 edition of the peer-reviewed, Journal of Diabetes Science and Technology.
“The scientific rationale for Glassia to treat T1D is based on the anti-inflammatory and immunoregulatory activities that AAT holds, which support beta-cells recovery processes from autoimmuno-mediated tissue injury.
http://www.marketwatch.com/story/ka...of-diabetes-science-and-technology-2014-10-21
“The scientific rationale for Glassia to treat T1D is based on the anti-inflammatory and immunoregulatory activities that AAT holds, which support beta-cells recovery processes from autoimmuno-mediated tissue injury.
http://www.marketwatch.com/story/ka...of-diabetes-science-and-technology-2014-10-21